Chronic Kidney Diseases
Pipeline by Development Stage
Drug Modality Breakdown
Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.
Key Trends
- GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
- Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
- Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research
Career Verdict
Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 25% | Peak | Stable | 12.4yr |
| 2 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 24% | Peak | Stable | 8.6yr |
| 3 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 20% | Peak | Stable | |
| 4 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 12% | Peak | Stable | 15.4yr |
Drug Class Breakdown
cardiometabolic dominance
cardioprotective expansion
heart failure crossover
overactive bladder niche
declining relevance
Career Outlook
StableNephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.
Breaking In
Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.
For Experienced Professionals
Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.
In-Demand Skills
Best For
Hiring Landscape
Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.
Top Hiring Companies
By Department
Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.
Competitive Landscape
44 companies ranked by most advanced pipeline stage
+14 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 5,013,270 patients across 50 trials
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
Immunogenicity of HPV Vaccine in Transplant Recipients.
Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus
A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
Bone in CKD Alkali Response (BICARb Pilot Trial)
COVID-19 Vaccine Boosters in Patients With CKD
Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
Acute Equol Supplementation and Vascular Function in Women With and Without CKD
A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria
Ferric Citrate and Chronic Kidney Disease in Children
Dapagliflozin in Non-diabetic Stage IV CKD
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Curcumin and Vascular and Cognitive Function in Patients With Chronic Kidney Disease
Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria
Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension
Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease
Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia
Safety of and Tolerability to a Sodium-free Peritoneal Dialysis Solution
Material Balance Study of TQ-B3525
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
Assessment of Renal Vasculature and Function with Ferumoxytol-enhanced Magnetic Resonance Imaging
A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001
Clinical Performance of a Point-of-Care Creatinine Testing System in Individuals With Kidney Disease
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
Chronic Kidney Disease Registry Platform Study
Intra Dialytic Parenteral Nutrition and Nutritional Gap Nutritional Gap Identified by Indirect Calorimetry
Decision Support for Detection of Chronic Kidney Disease in Type II Diabetes Mellitus
Multiparametric MRI in Healthy Volunteers and CKD Patients
Kidney AI-enabled Care Transformation
Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
Sleep-time Blood Pressure and Risk of CKD Progression
Inspiratory Muscle Strength Training in Chronic Kidney Disease
Double-Blind, Placebo-Controlled Trial of Eefooton in Patients With Chronic Kidney Disease
REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions.
SelfWrap-Assisted Arteriovenous Fistulas
Nova Max Creatinine and eGFR Meter System
The Role of the Kidneys and Liver in the Elimination of Glucagon
Chinese Chronic Renal Insufficiency Study: Based on Smartphone Platform
Smarter Care Virginia, Examining Low-Value Care in Virginia
National Unified Renal Translation Research Enterprise - Chronic Kidney Disease
Related Jobs in Nephrology
Junior CAD Designer (Solidworks)
Field Service Engineer II (Andover, MA)
Sr. R&D Engineer, Instruments - Pleasanton, CA
Director, Field Reimbursement (West)
Director, Field Reimbursement (Central)
Project Manager, On-Market Products - Pleasanton, CA
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.